Skip to main
LONA

LeonaBio Inc (LONA) Stock Forecast & Price Target

LeonaBio Inc (LONA) Analyst Ratings

Based on 3 analyst ratings
Buy
Strong Buy 0%
Buy 100%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

LeonaBio is a clinical-stage biopharmaceutical company with a positive outlook as it focuses on developing novel therapeutics for unmet medical needs. Its lead drug candidates, lasofoxifene and ATH-1105, show promising results for the treatment of metastatic breast cancer and ALS. The company's strategy of combining its drugs with other treatments could position them as a top choice for physicians in the evolving 2L ER+/HER2-mBC market, potentially leapfrogging other novel endocrine therapies. With strong clinical data and a well-funded pipeline, LeonaBio's stock is undervalued compared to its potential market share and potential label expansions.

Bears say

LeonaBio is a clinical-stage biopharmaceutical company that has demonstrated positive results with its novel drugs lasofoxifene and ATH-1105 in their respective clinical trials. However, the company's former program for Alzheimer's Disease failed to meet endpoints, raising concerns about the success of their current and future drug candidates. Additionally, while the company has raised significant funding through an IPO and equity financing, it has yet to generate any revenue, making it a risky investment at this stage.

LeonaBio Inc (LONA) has been analyzed by 3 analysts, with a consensus rating of Buy. 0% of analysts recommend a Strong Buy, 100% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of LeonaBio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About LeonaBio Inc (LONA) Forecast

Analysts have given LeonaBio Inc (LONA) a Buy based on their latest research and market trends.

According to 3 analysts, LeonaBio Inc (LONA) has a Buy consensus rating as of Aug 30, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $17.33, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $17.33, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

LeonaBio Inc (LONA)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.